Medite Cancer Diagnostics, Inc. (MDIT)

Market Cap	8.58K +9,877.9%
Revenue (ttm)	8.13M +19.5%
Net Income	-5.42M
EPS	-0.11
Shares Out	85.81M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	380
Open	0.0001
Previous Close	0.0001
Day's Range	0.0001 - 0.0001
52-Week Range	0.000001 - 0.0050
Beta	525.49
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Medite Cancer Diagnostics

Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue s...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Employees: 69
• Stock Exchange: OTCMKTS
• Ticker Symbol: MDIT

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 25, 2026

Data Sources Report a data error